Varinos, a Tokyo genomics company best known for its uterine-flora test for fertility patients, has acquired all of the shares of MySkin, a University of Tokyo spinout that analyses the bacteria living on human skin. Varinos announced the deal on November 9, 2026, in a press release on PR TIMES; the share purchase took effect on November 1.
The price was not disclosed. MySkin will continue under its own name as part of the Varinos group, with Yasuhiro Nishi staying on as president and chief executive. Varinos chief executive Yoichi Saito and president Hidetoshi Hirakawa have joined MySkin's board, and a Varinos auditor has become MySkin's auditor.
Varinos said the deal is the first step in expanding its genome and microbiome analysis business beyond reproductive medicine into wider medical and healthcare markets, and in building up contract analysis and joint research for cosmetics, pharmaceutical and healthcare companies.
What MySkin built
MySkin was founded in January 2014 as a University of Tokyo venture, set up to commercialise research from the university's Institute for Quantitative Biosciences, according to Nishi's comment in the release. It is based in Bunkyo-ku, Tokyo, near the university's main campus.
The company describes itself as a biotech business focused on the skin microbiome. Its core asset is a patented sampling kit, sold as the MySkin kit, which it says is simple to use and suited to large-scale, quantitative studies. It handles the whole process from sampling through analysis and evaluation.
Most of MySkin's work is done for other companies. It analyses skin bacteria and evaluates microbial communities on contract for large manufacturers, healthcare companies and research institutes, and runs joint research projects. Typical jobs include basic research for new products, profiling of microbial communities and measuring how a product changes the skin's bacteria before and after use. MySkin's revenue, headcount and past investors were not disclosed.
Why Varinos is buying
Varinos was founded in February 2017 and is based in Koto-ku, Tokyo. In 2017 it brought to market what it calls the world's first test that comprehensively analyses the tiny amounts of bacteria in the uterus, and in June 2022 the test was approved under Japan's advanced medical care scheme. The test is used at more than 400 medical institutions in Japan, mainly fertility clinics, and more than 50,000 samples have been analysed, the company says. It also offers preimplantation genetic testing and other genomic tests for assisted reproduction.
The two companies work in the same field, microbiome analysis, but from different directions. Varinos said its strengths are turning research into clinical tests and its network of medical institutions, while MySkin brings patented technology and relationships across industry. Combining them, Varinos said, lets the group offer everything from developing new genomic tests and running advanced analysis to clinical use and joint research with companies.
Hirakawa said in the release that bringing MySkin into the group is an important step that will further speed up Varinos's growth strategy, and that the companies will share staff and business infrastructure as well as technology.
The funding behind the buyer
Varinos is itself a venture-backed company. Dealroom reported that it raised about $9.62 million in a Series D round in May 2026, with Mitsui Chemicals among the investors, to fund business beyond its core testing. Dealroom's data lists Varinos as having raised about $14 million in total.
Varinos has won several start-up awards in Japan, including the Minister of Economy, Trade and Industry award at the Japan Venture Awards 2020, according to its company profile in the release.
From the womb to the skin
Nishi said MySkin would keep refining its analysis technology as part of the Varinos group and aim to expand into medical and healthcare uses alongside its existing work. Varinos said that after MySkin it plans to offer services in a range of medical and healthcare fields beyond fertility and skin, serving medical institutions, patients, companies and research bodies.




